97 results
10-Q
2024 Q2
EX-10.1
IMNM
Immunome, Inc.
Quarterly report
12 Aug 24
4:10pm
10-K
2023 FY
EX-10.18
IMNM
Immunome, Inc.
Annual report
28 Mar 24
4:06pm
10-K
2023 FY
EX-10.30
IMNM
Immunome, Inc.
Annual report
28 Mar 24
4:06pm
10-K
2023 FY
EX-10.16
IMNM
Immunome, Inc.
Annual report
28 Mar 24
4:06pm
10-K
2023 FY
EX-10.20
IMNM
Immunome, Inc.
Annual report
28 Mar 24
4:06pm
8-K
EX-10.1
086pxwzujx4b
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
8-K
EX-10.1
7xxq q7ogpknc7e
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-10.2
389nsy69s gw1g1
29 Dec 23
Departure of Directors or Certain Officers
5:00pm
8-K
EX-10.1
tn1ywttwgx35707k
29 Dec 23
Departure of Directors or Certain Officers
5:00pm